Claimed effect · CJC-1295

Does CJC-1295 help with growth hormone / IGF-1 elevation?

B
Grade B — probable, not settledPhase 1 / early phase 2 · effect size: large
Short answerProbable, not settled. Human data exist (Phase 1 / early phase 2) and mostly agree, showing a large effect — but too few, too small, or not yet peer-reviewed for a firm answer. Weekly dosing produced sustained multi-fold GH increases and IGF-1 elevations over weeks in healthy adults — a large, reproducible effect on the marker.

What the studies show

Weekly dosing produced sustained multi-fold GH increases and IGF-1 elevations over weeks in healthy adults — a large, reproducible effect on the marker.

“After a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 d.”

Verbatim, from the abstractTeichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults. J Clin Endocrinol Metab, 2006;91:799–805

Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.

  1. 1

In context

CJC-1295 is a modified growth-hormone-releasing hormone fragment engineered to bind albumin so that it lasts days rather than minutes. Early human trials showed substantial, sustained rises in growth hormone and IGF-1 with weekly dosing. Development was discontinued and no trial has measured whether that translates into any clinical outcome. It is not approved anywhere and is banned in sport.

CJC-1295 is not approved. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is CJC-1295 proven to help with growth hormone / IGF-1 elevation?
Not yet settled. Phase 1 / early phase 2 — LYO grades it B, meaning probable but liable to change as trials read out.
What studies are behind the grade?
Weekly dosing produced sustained multi-fold GH increases and IGF-1 elevations over weeks in healthy adults — a large, reproducible effect on the marker.
Is CJC-1295 approved for this?
No. CJC-1295 is not approved; it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for CJC-1295

Written and maintained by LYO Research — how pages are written and checked. Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →